ReviewFrontiers in oncology2020
Sequence-Based Characterization of Intratumoral Bacteria-A Guide to Best Practice.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Intratumoral microbiota in cancer immunotherapy: metabolic-epigenetic crosstalk and engineered bacterial therapeutics.Experimental hematology & oncology · 2026Review
- Review
- Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.Journal of advanced research · 2026Review
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- Bioengineered bacteria in cancer immunotherapy: mechanistic advances, therapeutic strategies and clinical potential.Archives of microbiology · 2026Review
- Tissue biobanking: minimum interface requirements for efficient and high-quality support for biomedical research - a white paper.Virchows Archiv : an international journal of pathology · 2026Article
- Fusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression.Clinical and translational medicine · 2026Review
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Deciphering the intratumor microbiota in malignant gastrointestinal tumors: multifaceted interplay and clinical implications.Cell communication and signaling : CCS · 2026Review
- Multi-omics Analysis Reveals How Intratumoral Bacteria Shape the Immune Microenvironment in Gastric Cancer.Genomics, proteomics & bioinformatics · 2025Article
- Human colitis-associated colorectal carcinoma progression is accompanied by dysbiosis with enriched pathobionts.Gut microbes · 2025Article
- Primary tumor microbiomes predict distant metastasis of colorectal cancer.NPJ precision oncology · 2025Article
- Specific Intratumoral Microbiome Signatures in Human Glioblastoma and Meningioma: Evidence for a Gut-Brain Microbial Axis.International journal of molecular sciences · 2025Article
- Tumor-associated microbiota: Multi-cancer landscape, mechanistic insights and clinical translation (Review).Oncology letters · 2025Review
- Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis.Molecular cancer · 2025Article
- Impact of study design, contamination, and data characteristics on results and interpretation of microbiome studies.mSystems · 2025Article
- Article
- Temporal changes in the bacterial microbiome of the salivary gland and midgut tissues of Rhipicephalus sanguineus (s.l.) ticks in South Africa.Scientific reports · 2025Article
- Intratumoral microbiota for hepatocellular carcinoma: from preclinical mechanisms to clinical cancer treatment.Cancer cell international · 2025Review
- Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota.Cell death discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors are hospitable environments to bacteria and several recent studies on cancer patient samples have introduced the concept of an endogenous tumor microbiome. For a variety of reasons, this putative tumor microbiome is particularly challenging to investigate, and a failure to account for the various potential pitfalls will result in erroneous results and claims. Before this potentially extremely medically-significant habitat can be accurately characterized, a clear understanding of all potential confounding factors is required, and a best-practice approach should be developed and adopted. This review summarizes all of the potential issues confounding accurate bacterial DNA sequence analysis of the putative tumor microbiome, and offers solutions based on related research with the hope of assisting in the progression of research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.